Table 1.
Patient characteristics.
| Total | Typical CIDP | Atypical CIDP | MMN | HC | Baseline statistic | |
|---|---|---|---|---|---|---|
| Demographics | 63 | 31 (45%) | 32 (46%) | 6 (9%) | 40 | |
| Sex | ||||||
| Male | 38 (60%) | 14 (45%) | 24 (75%) | 4 (80%) | 17 (43%) | 17 (43%) p = 0.0256* |
| Age at time point of sampling (years) | 63.7 ± 11.9 | 59.6 ± 17.3 | 64.1 ± 10.9 | 62.2 ± 11.1 | 48.1 ± 8.5 | 48.1 ± 8.5 p <0.001* |
| Disease duration (years) | 8.0 (4.0–12.0) | 9.5 (3.3–16.8) | 7.0 (4.0–10.0) | 5.0 (3.8–14.8) | – | |
| EFNS/PNS criteria | ||||||
| Definite | 33 (52%) | 18 (58%) | 15 (48%) | 6 (100%) | – | |
| Probable | 30 (48%) | 13 (42%) | 17 (52%) | 0 (0%) | ||
| Disease activity status | ||||||
| Active stabile | 51 (81%) | 26 (84%) | 25 (78%) | 6 (100%) | – | |
| Remission | 12 (19%) | 5 (16%) | 7 (22%) | 0 (0%) | ||
| INCAT-score (SD) | ||||||
| Arms | 1.4 (0.9) | 1.6 (1.1) | 1.5 (1.0) | 2.0 (0.6) | – | |
| LEGS | 1.3 (0.7) | 1.6 (0.9) | 1.4 (0.8) | 1.2 (0.8) | ||
| Grip strength KPA (SD) | ||||||
| Right arm | 68.3 (23.3) | 66.7 (27.6) | 74.3 (19.2) | 53.2 (19.5) | ||
| Left arm | 63.1 (26.9) | 61.5 (28.4) | 70.5 (21.5) | 65.6 (25.7) | – | |
| Medical research council (SD) | 74.3 (4.6) | 73.1 (9.1) | 72.3 (7.6) | 73.0 (6.1) | – | |
| Max. walking distance in meters | 1,000 (200–3,250) | 1,000 (200–2,000) | 1,000 (500–4,750) | 5,500 (400–32,500) | – | |
| Median (IQR) | ||||||
| SF-36 TOTAL (SD) | 78.4 (16.5) | 79.2 (16.2) | 77.7 (17.4) | 68.5 (14.9) | – | |
| SF-36 PSC (SD) | 32.2 (10.2) | 30.9 (6.9) | 34.1 (11.8) | 37.9 (14.6) | – | |
| SF-36 MSC (SD) | 44.4 (13.5) | 47.1 (12.0) | 42.3 (14.5) | 30.5 (0.6) | – | |
| FSS (SD) | 4.6 (1.7) | 4.8 (1.8) | 4.5 (1.8) | 5.3 (1.4) | – | |
| BDI (SD) | 12.3 (8.3) | 8.4 (2.0) | 12.3 (8.5) | 19.3 (5.5) | – | |
| Treatment | ||||||
| Corticosteroids | 8 (12%) | 6 (19%) | 2 (6%) | 0 (0%) | – | |
| IVIG | 35 (56%) | 17 (55%) | 18 (56%) | 5 (84%) | – | |
| Plasmapheresis | 4 (10%) | 2 (7%) | 2 (6%) | 0 (0%) | – | |
| AZT/MMF | 4 (10%) | 3 (10%) | 1 (3%) | 0 (0%) | – | |
| Rituximab | 3 (4%) | 2 (7%) | 1 (3%) | 0 (0%) | – |
Data are mean (SD) and n (%) for the baseline variables and median (IQR) for disease duration. Disease duration is the time from diagnosis until baseline. AZT/MMF, azathioprine/mycophenolate mofetil; CIDP, chronic inflammatory demyelinating polyneuropathy; EFNS/PNS, European Federation of Neurological Societies/Peripheral Nerve Society; HC, healthy controls; INCAT, inflammatory neuropathy cause and treatment sensory sum score; IVIG, intravenous immunoglobulins; IQR, interquartile range; MMN, multifocal motoric neuropathy; MRC, medical research council sum score; SD, standard deviation; –, not applicable;
*
statistical analysis was performed using Mann–Whitney U-test.